Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Salmonella protein can reduce drug resistant molecule found in cancer cells

A surprising result in an experiment on Salmonella bacteria has led to a discovery that may make drug resistant cancer cells more treatable by conventional chemotherapies.

25 Jul 2016

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.

21 Jul 2016

Researchers propose new approach to target chemotherapy medications specifically to sarcomas

Sarcoma is an aggressive form of cancer responsible for up to 20 percent of childhood cancers. Tumors often first appear in the extremities and the abdomen. Surgery is a primary treatment, but it often is combined with chemotherapy.

15 Jul 2016

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.

30 Jun 2016

New drug-capture device can soak up chemotherapy drugs to limit toxicity

Doctors have a powerful arsenal of cancer-fighting chemotherapy drugs to choose from, though a key challenge is to better target these drugs to kill tumors while limiting their potentially harmful side effects.

8 Jun 2016

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth.

20 May 2016

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab.

19 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

Scientists successfully turn off misbehaving protein that fuels growth of triple-negative breast cancer

Working with human breast cancer cells, a team of scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have successfully turned off a misbehaving protein that fuels the growth of a particularly aggressive, drug-resistant form of the disease known as triple-negative breast cancer.

5 Apr 2016

Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

An innovative cancer treatment made of luminescent chemotherapy-filled beads injected into tumors through the wrist is now available for patients with inoperable and difficult-to-treat liver cancer.

23 Mar 2016

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice.

15 Mar 2016

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries.

10 Mar 2016

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain's protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer.

26 Feb 2016

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.

26 Feb 2016

Researchers analyze how Topo II enzyme may affect stability of genomes

While researchers are now familiar with how cancer begins—cells mutate and then multiply wildly out of control—it is still uncertain exactly how that mutation starts in the molecules of the cells.

22 Feb 2016

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

PharmaMar announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.

8 Feb 2016

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

St. Jude Children's Research Hospital scientists have discovered how an aggressive tumor of the muscle and soft tissue hijacks an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy.

22 Dec 2015

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants.

13 Dec 2015

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015